Overview

Secretin for the Treatment of Autism

Status:
Completed
Trial end date:
2000-05-01
Target enrollment:
Participant gender:
Summary
Many drugs used to treat autism target specific symptoms, such as hyperactivity and aggressiveness. Few drugs target the core autistic symptoms of impaired social interaction and communication. This study will evaluate two forms of the drug secretin for the treatment of core autistic symptoms.
Phase:
Phase 3
Details
Lead Sponsor:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Collaborator:
National Institute on Deafness and Other Communication Disorders (NIDCD)
Treatments:
Secretin